20%
of the population experiences moderate to severe chronic pain.
Ending
Chronic pain
Towards a world where every patient has access to safe and effective treatments for chronic pain.
First
We’re the first biotech developing Precision Pump Modulators (PPMs) for pain, a novel class of non-opioid medicines.
FXYD2
Dolinnov is the world’s first biotech company dedicated to targeting FXYD2, a regulator of neuronal excitability in the DRG.
Our mission
At Dolinnov, we envision a world where every patient has access to safe and effective treatments for chronic pain. We are building a new generation of non-opioid medicines: precise, effective, and free from the burden of addiction. Our mission is to transform the lives of the hundreds of millions living with chronic pain.
Transforming innovation into the next generation of pain relief
Innovative target
- The FXYD2 protein, also known as the gamma subunit of the Na+/K+-ATPase, plays a regulatory role in ion transport and neuronal excitability.
- As a peripheral nervous system target, FXYD2 offers a unique opportunity for precise therapeutic intervention, minimizing potential side effects on central nervous system functions.
Precision therapeutic modality
- Dolinnov is the first company worldwide to develop a lipid antisense oligonucleotide (L-ASO) therapy specifically targeting pain.
- Our patented proprietary conjugated L-ASO chemistry enables groundbreaking efficacy.
A Broad Spectrum of Indications
- Our new therapeutic approach targets both neuropathic and inflammatory pain, offering a comprehensive solution for chronic pain management.
- Priority indications include severe cancer pain and rare disorders associated to pain.
What immediately inspired me to join this project was its groundbreaking approach to targeting this mechanism—a causal and 'circuit-breaking' strategy for pain management. Combined with the exceptional quality of the underlying science, it redefines treatment paradigms, effectively addressing the primary barriers to patient care.
It is the extraordinary motivation of a researcher to transform a groundbreaking academic discovery from my thesis into a preclinical reality, with the goal of revolutionizing patient care and advancing the frontiers of medicine.
Dolinnov is a unique opportunity to convert a high-level academic scientific project into a groundbreaking enterprise. I am committed to dedicating my full energy to turning this project into a clinical reality that will make a difference for patients.
Investing in Dolinnov is above all about supporting a highly mature, scientific disruptive project with the potential to deliver game-changing treatment solutions. It also means placing trust in a strong and dedicated team capable of making this vision a clinical reality.
Dolinnov is a unique opportunity to convert a high-level academic scientific project into a groundbreaking enterprise. I am committed to dedicating my full energy to turning this project into a clinical reality that will make a difference for patients.
It is the extraordinary motivation of a researcher to transform a groundbreaking academic discovery from my thesis into a preclinical reality, with the goal of revolutionizing patient care and advancing the frontiers of medicine.
What immediately inspired me to join this project was its groundbreaking approach to targeting this mechanism—a causal and 'circuit-breaking' strategy for pain management. Combined with the exceptional quality of the underlying science, it redefines treatment paradigms, effectively addressing the primary barriers to patient care.
Investing in Dolinnov is above all about supporting a highly mature, scientific disruptive project with the potential to deliver game-changing treatment solutions. It also means placing trust in a strong and dedicated team capable of making this vision a clinical reality.
Partners supporting the project
Design with by the gang